Iparomlimab
Consolidation Immunotherapy
Shanghai Chest HospitalPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 89/ 100
Competitive context
6 Active assets in the Consolidation Immunotherapy cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Carboplatin Shanghai Chest Hospital | Phase 2 | CCC |
ETOPOSIDE Shanghai Chest Hospital | Phase 2 | CCC |
Tislelizumab Peking University Cancer Hospital & Institute | Phase 2 | CCC |
CIS-DIAMMINEDICHLOROPLATINUM II Shanghai Chest Hospital | Phase 2 | CCC |
Pyrotinib Peking University Cancer Hospital & Institute | Phase 2 | CCC |
rc48-adc Peking University Cancer Hospital & Institute | Phase 2 | CCC |
Same molecule, other indications
Iparomlimab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →